Literature DB >> 10449560

Different clinical aspects of debrancher deficiency myopathy.

S Kiechl1, U Kohlendorfer, C Thaler, D Skladal, M Jaksch, B Obermaier-Kusser, J Willeit.   

Abstract

OBJECTIVE: To characterise the main clinical phenotypes of debrancher deficiency myopathy and to increase awareness for this probably underdiagnosed disorder.
METHODS: The diagnosis of debrancher deficiency was established by laboratory tests, EMG, and muscle and liver biopsy.
RESULTS: Four patients with debrancher deficiency myopathy were identified in the Tyrol, a federal state of Austria with half a million inhabitants. Clinical appearance was highly variable. The following phenotypes were differentiated: (1) adult onset distal myopathy; (2) subacute myopathy of the respiratory muscles; (3) severe generalised myopathy; and (4) minimal variant myopathy. Exercise intolerance was uncommon. The clinical course was complicated by advanced liver dysfunction in two patients and by severe cardiomyopathy in one. All had raised creatine kinase concentrations (263 to 810 U/l), myogenic and neurogenic features on EMG, and markedly decreased debrancher enzyme activities in muscle or liver biopsy specimens. The findings were substantiated by a review of 79 previously published cases with neuromuscular debrancher deficiency.
CONCLUSIONS: This study illustrates the heterogeneity of neuromuscular manifestations in debrancher deficiency. Based on the clinical appearance, age at onset, and course of disease four phenotypes may be defined which differ in prognosis, frequency of complications, and response to therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10449560      PMCID: PMC1736538          DOI: 10.1136/jnnp.67.3.364

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  39 in total

1.  Amylo-1, 6-glucosidase in muscle tissue in generalized glycogen storage disease.

Authors:  B ILLINGWORTH; G T CORI; C F CORI
Journal:  J Biol Chem       Date:  1956-01       Impact factor: 5.157

2.  Biochemical investigation of an unusual case of glycogenosis.

Authors:  P Ozand; M Tokatli; S Amiri
Journal:  J Pediatr       Date:  1967-08       Impact factor: 4.406

3.  Motor neuron disease presenting with respiratory failure.

Authors:  M de Carvalho; T Matias; F Coelho; T Evangelista; A Pinto; M L Luís
Journal:  J Neurol Sci       Date:  1996-08       Impact factor: 3.181

4.  A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12-->G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb.

Authors:  M Okubo; A Horinishi; N Nakamura; Y Aoyama; M Hashimoto; Y Endo; T Murase
Journal:  Hum Genet       Date:  1998-01       Impact factor: 4.132

5.  Respiratory insufficiency in neuronopathic and neuropathic disorders.

Authors:  R M Chalmers; R S Howard; C M Wiles; N P Hirsch; D H Miller; A Williams; G T Spencer
Journal:  QJM       Date:  1996-06

6.  Debrancher deficiency neuromuscular disorder with pseudohypertrophy in two brothers.

Authors:  A Marbini; F Gemignani; F Saccardi; M Rimoldi
Journal:  J Neurol       Date:  1989-10       Impact factor: 4.849

7.  Myopathy and growth failure in debrancher enzyme deficiency: improvement with high-protein nocturnal enteral therapy.

Authors:  A E Slonim; R A Coleman; W S Moses
Journal:  J Pediatr       Date:  1984-12       Impact factor: 4.406

Review 8.  Glycogen storage disease in adults.

Authors:  G M Talente; R A Coleman; C Alter; L Baker; B I Brown; R A Cannon; Y T Chen; J F Crigler; P Ferreira; J C Haworth; G E Herman; R M Issenman; J P Keating; R Linde; T F Roe; B Senior; J I Wolfsdorf
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

9.  Acid maltase deficiency in adults presenting as respiratory failure.

Authors:  E C Rosenow; A G Engel
Journal:  Am J Med       Date:  1978-03       Impact factor: 4.965

10.  Inclusion body myositis as a cause of respiratory failure.

Authors:  R Cohen; S Lipper; D R Dantzker
Journal:  Chest       Date:  1993-09       Impact factor: 9.410

View more
  7 in total

Review 1.  Myopathies Related to Glycogen Metabolism Disorders.

Authors:  Mark A Tarnopolsky
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 2.  Muscle glycogenoses: an overview.

Authors:  S Di Mauro
Journal:  Acta Myol       Date:  2007-07

Review 3.  Physical therapy assessment and whole-body magnetic resonance imaging findings in children with glycogen storage disease type IIIa: A clinical study and review of the literature.

Authors:  Anna Paschall; Aleena A Khan; Syed Faaiz Enam; Tracy Boggs; Ghada Hijazi; Michael Bowling; Stephanie Austin; Laura E Case; Priya Kishnani
Journal:  Mol Genet Metab       Date:  2021-10-09       Impact factor: 4.797

Review 4.  Inborn errors of energy metabolism associated with myopathies.

Authors:  Anibh M Das; Ulrike Steuerwald; Sabine Illsinger
Journal:  J Biomed Biotechnol       Date:  2010-05-26

Review 5.  Differential diagnosis of idiopathic inflammatory myopathies.

Authors:  Alan N Baer
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.686

6.  Effects of acute nutritional ketosis during exercise in adults with glycogen storage disease type IIIa are phenotype-specific: An investigator-initiated, randomized, crossover study.

Authors:  Irene J Hoogeveen; Foekje de Boer; Willemijn F Boonstra; Caroline J van der Schaaf; Ulrike Steuerwald; Anita J Sibeijn-Kuiper; Riemer J K Vegter; Johannes H van der Hoeven; M Rebecca Heiner-Fokkema; Kieran C Clarke; Pete J Cox; Terry G J Derks; Jeroen A L Jeneson
Journal:  J Inherit Metab Dis       Date:  2020-09-07       Impact factor: 4.982

7.  Aerobic capacity and skeletal muscle characteristics in glycogen storage disease IIIa: an observational study.

Authors:  Philip J Hennis; Elaine Murphy; Rick I Meijer; Robin H Lachmann; Radha Ramachandran; Claire Bordoli; Gurinder Rayat; David J Tomlinson
Journal:  Orphanet J Rare Dis       Date:  2022-01-31       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.